Virtual Library
Start Your Search
L. Gasiorowski
Author of
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-086 - An Effective In Vivo Liquid Biopsy Tool for High-Yield Isolation of Circulating Tumor Cells (ID 3245)
09:30 - 09:30 | Author(s): L. Gasiorowski
- Abstract
Background:
Analysis of tumor biopsy material represents only assessable tumor and represents the state at the time of diagnosis. This approach neglects tumoral heterogeneity changes occurring during disease progression. However, during systemic therapies tumors undergo molecular changes and usually develop resistance mechanisms. Reevaluation of tumors after therapy, at disease progression and before new treatment initiation would be informative for the selection of appropriate next steps. However, re-biopsies are not often feasible and can cause morbidity. . Liquid biopsy, i.e. isolating and analyzing circulating tumor cells (CTCs), can be an additional source of diagnosis, prognosis, evaluation of treatment efficacy, and molecular tumor evolution and metastatic sites. Commonly, CTCs are isolated from small blood volumes (5-10 ml) in in vitro approaches. This approach has limited sampling volume particularly in detecting low frequency CTC. To overcome this limitation, the GILUPI CellCollector[â], an intravascularly in-dwelling device, screens a large volume (>1 liter) of blood for CTCs directly in the vein of the cancer patient. The device has specific monoclonal antibodies attached to pull down epithelial derived CTCs. We demonstrate the application of the CellCollector in the assessment of CTC in non-small cell lung cancer (NSCLC) patients. The novel study demonstrates a novel in vivo approach of assessing CTC in different stages of NSCLC.
Methods:
: In this study a total of 25 non-small cell lung cancer (NSCLC) patients stage IA to IIIB, were applied for CTC isolation before (n=50) time and after surgery how long after (n=25). CTC validation and enumeration was conducted by immunofluorescence (IF) microscopy. Following this, isolated CTCs were analysed for mutations in KRAS and EGFR genes commonly found in NSCLC using the PointMan DNA mutation enrichment assay. Primary tumor tissue was analysed for the same mutations to investigate concordance.
Results:
In a previous studies have shown a significantly higher isolation efficacy compared to the FDA-cleared CellSearch[â] System. In the current study we focused on the comparison of the status of driver mutations in KRAS and EGFR in CTCs compared to the primary tumor tissue. Overall, successful isolation of CTCs with the CellCollector[â] was detectable in 77% of the samples. The pre-surgical isolation rate was 79%, slightly higher than the post-operative rate of 72%. In this cohort of patients, EGFR and KRAS mutations could be detected in all patients? Frequency level need to given and were compared by analysis of the respective primary tumor sgive concordance.
Conclusion:
The GILUPI CellCollector[â] overcomes blood volume limitations of other CTC extraction approaches and thereby increases the diagnostic sensitivity of CTC isolation. It allows CTC enumeration, molecular characterization, and biomarker expression analysis, which could help guide treatment strategies and monitoring therapy efficacy.
